Sartorius Stedim Bio (SDMHF) 178.6600 $SDMHF
Research and Markets: Global Single-Use Bio-Processing Systems Market 2014-2018 With GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
Business Wire - Thu Jul 17, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twp8ts/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering.
Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
M2 - Thu Jul 17, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dkzwqv/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering. The Global Single-use Bio-processing Systems market will grow at a CAGR of 38% to 2018 The report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Owing to the growing potential of the Global Single-use Bio-processing Systems market, many bio-processing systems manufacturers collaborate to develop new platforms for the cultivation of cells or to develop new systems. For example, Sartorius's collaboration with Refine Technology LLC for the development of a robust platform for high-density cell cultivation. This platform will enable fast and easy connection of the alternating tangential flow system to Sartorius Stedim Biotech's field-proven single-use BIOSTAT bioreactors. Moreover, the partnership would enable the development of new designs of clinical analyzers and enable vendors to stay competitive in the market. This in turn could boost the growth of the Global Single-use Bio-processing Systems market. According to the report, the increasing demand for biopharmaceuticals is one of the major drivers in this market. The aging population in the US is expected to double and reach a total of 71 million by 2030. Cardiovascular diseases, Alzheimer's, and cancer are some of the most common diseases seen in the aged. Therefore, the steadily growing aging population increases the prevalence of these diseases, which in turn increases the demand for biopharmaceuticals. Further, the report states that the implementation of stringent regulations is one of the major challenges faced by the vendors in this market. Currently, the regulations for single-use bio-processing systems are not completely defined and documented, because the FDA has been quite liberal in not imposing more stringent regulations. However, the regulations are still uncertain owing to the limited usage of single-use bio-processing systems in commercial production. Key Vendors - GE Healthcare - Merck & Co Inc. - Sartorius Stedim Biotech SA - ThermoFisher Scientific Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Applications - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dk..._singleuse
MRK: 59.07 (-0.47)
Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018
M2 - Fri Mar 14, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfm638/pharmaceutical) has announced the addition of the "Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018" report to their offering. Membrane filtration is a widely used separation technique in pharmaceutical and biotechnology industries. It finds extensive applications in the biopharmaceutical industry as biopharmaceutical products and their intermediates are susceptible to degradation due to heat and chemical treatment, and so are difficult to separate using other techniques. Membrane filtration has been used in pharmaceutical industry since 1935 and it is presently one of the most widely adopted separation techniques in this industry. The global pharmaceutical membrane filtration market is segmented on the basis of technology, application, and region. The technology segments included in the report are microfiltration, ultrafiltration, nanofiltration, reverse osmosis, and ion exchange; the application segments are cell separation, protein purification, sterilization, virus removal, and water management; while the geographic segments are North America, Europe, Asia-Pacific, and Rest of the World (RoW). The major factor driving the growth of this market is the growth of the global pharmaceutical industry. The adoption rate of membrane filtration in Europe and North America is very high. Further, increasing adoption rate in the Asia-Pacific segment and increasing demand for single use technology will further drive this market. Therefore, the pharmaceutical membrane filtration market is expected to witness a high growth in the forecast period. Membrane filtration is also used widely for protein purification in the pharmaceutical industry. Other important applications of this technology in the pharmaceutical industry are cell separation and water treatment. Microfiltration and ultrafiltration are the most widely used filtration technologies in the pharmaceutical industry. In 2013, Europe was the largest market for pharmaceutical membrane filtration. However, the North American market is expected to grow rapidly in the forecast period between 2013 and 2018 and is expected to be as large as that of Europe by 2018. Reasons to Buy the Report: - Market Penetration: Comprehensive information on product portfolios of top players in the pharmaceutical membrane filtration market. The report analyzes the pharmaceutical membrane filtration market by application across geographies. - Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical membrane filtration market. - Market Diversification: Exhaustive information about new technologies, applications, and emerging geographies in the pharmaceutical membrane filtration market. - Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the pharmaceutical membrane filtration market. Key Topics Covered: Introduction Executive Summary Market Dynamics Pharmaceutical Membrane Filtration Market - By Technology Pharmaceutical Membrane Filtration Market - By Application Pharmaceutical Membrane Filtration Market - By Geography Competitive Landscape Company Profiles List of Tables Companies Mentioned - 3M - Alfa Laval - GE - GEA Group - Graver Technologies - Koch Membrane Systems - MECO - Merck Millipore - Novasep - Pall Corporation - Sartorius Stedim Biotech - Spectrum Laboratories For more information visit http://www.researchandmarkets.com/research/kf...maceutical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PLL: 93.46 (-0.32), MRK: 59.07 (-0.47)
Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
M2 - Tue Aug 13, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq64s6/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets" report to their offering. 72 1024x768 Normal 0 false false false This new report, "Global Markets for Bioseparations for Biopharmaceutical Manufacturing," cites that the global market for bioseparations for biopharmaceutical manufacturing will grow to $6 billion by 2018. While North America and Europe will continue to account for a significant share of revenue, the emerging countries of China, India, Brazil and Russia are rapidly increasing share, growing at a CAGR of 22%. The demand for single use products is increasing and fueling growth of the global bioseparations market. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. The Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs, producing biosimilars for their own large populations and for Southeast Asia. bioseparations market. Membranes/filters will contribute $1.4 billion, followed by centrifuges ($400 million). The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report covers: Normal 0 false false false MicrosoftInternetExplorer4 The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report examines companies manufacturing biopharmaceutical manufacturing equipment and supplies in the world. Companies covered include: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/pq...separation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PLL: 93.46 (-0.32), A: 41.57 (+0.12), MRK: 59.07 (-0.47), DOW: 51.37 (+1.41), WAT: 112.48 (-1.24)
IV Fluid Transfer Devices Report - Products, Players, Markets and Opportunities
M2 - Wed Jun 26, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fnpmtc/iv_fluid_transfer) has announced the addition of the "IV Fluid Transfer Devices Products, Players, Markets and Opportunities" report to their offering. Intravenous drug administration is one of the most common therapeutic procedures that patients in a hospital setting are likely to receive. Yet the lack of standardization among the various components, elements and steps that a caregiver must navigate to successfully execute a drug intravenously have - according to several recent studies - contributed to medication errors and risks to patient safety. IV drug administration was once provided to patients only in clinical settings. However, technology developments and a greater emphasis on cost containment over the last 30 years have prompted a shift to providing this therapy in alternate settings, including the home. Highlights: - Analyzes the global market for IV fluid transfer devices market segments, and assesses the probable market
ICUI: 85.71 (+0.76), WST: 51.35 (-0.79), NVO: 44.13 (+0.11), CFN: 57.57 (+0.01)
ProMetic and Sartorius Stedim Biotech ("SSB"
Join Forces to Promote Novel Turnkey Solution for Producing Plasma-Derived Therapeutics
Marketwire - Tue Apr 30, 4:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB" to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPS(TM) on a global basis.
PLI.TO: 1.94 (-0.01)
Sartorius Stedim Biotech: Fact Sheet on New Reporting Format
Business Wire - Mon Apr 15, 1:32PM CDT
From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris
IM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech's business figures for 2012 as well as its earnings guidance for 2013 according to these changes.
Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media
Business Wire - Wed Dec 19, 12:00AM CST
--Long-term collaboration, supply and distribution agreement with Swiss-based life science group Lonza
Research and Markets: Global Single-Use Bio-Processing Systems Market 2014-2018 With GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
Business Wire - Thu Jul 17, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twp8ts/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering.
Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
M2 - Thu Jul 17, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dkzwqv/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering. The Global Single-use Bio-processing Systems market will grow at a CAGR of 38% to 2018 The report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Owing to the growing potential of the Global Single-use Bio-processing Systems market, many bio-processing systems manufacturers collaborate to develop new platforms for the cultivation of cells or to develop new systems. For example, Sartorius's collaboration with Refine Technology LLC for the development of a robust platform for high-density cell cultivation. This platform will enable fast and easy connection of the alternating tangential flow system to Sartorius Stedim Biotech's field-proven single-use BIOSTAT bioreactors. Moreover, the partnership would enable the development of new designs of clinical analyzers and enable vendors to stay competitive in the market. This in turn could boost the growth of the Global Single-use Bio-processing Systems market. According to the report, the increasing demand for biopharmaceuticals is one of the major drivers in this market. The aging population in the US is expected to double and reach a total of 71 million by 2030. Cardiovascular diseases, Alzheimer's, and cancer are some of the most common diseases seen in the aged. Therefore, the steadily growing aging population increases the prevalence of these diseases, which in turn increases the demand for biopharmaceuticals. Further, the report states that the implementation of stringent regulations is one of the major challenges faced by the vendors in this market. Currently, the regulations for single-use bio-processing systems are not completely defined and documented, because the FDA has been quite liberal in not imposing more stringent regulations. However, the regulations are still uncertain owing to the limited usage of single-use bio-processing systems in commercial production. Key Vendors - GE Healthcare - Merck & Co Inc. - Sartorius Stedim Biotech SA - ThermoFisher Scientific Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Applications - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dk..._singleuse
MRK: 59.07 (-0.47)
Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018
M2 - Fri Mar 14, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfm638/pharmaceutical) has announced the addition of the "Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018" report to their offering. Membrane filtration is a widely used separation technique in pharmaceutical and biotechnology industries. It finds extensive applications in the biopharmaceutical industry as biopharmaceutical products and their intermediates are susceptible to degradation due to heat and chemical treatment, and so are difficult to separate using other techniques. Membrane filtration has been used in pharmaceutical industry since 1935 and it is presently one of the most widely adopted separation techniques in this industry. The global pharmaceutical membrane filtration market is segmented on the basis of technology, application, and region. The technology segments included in the report are microfiltration, ultrafiltration, nanofiltration, reverse osmosis, and ion exchange; the application segments are cell separation, protein purification, sterilization, virus removal, and water management; while the geographic segments are North America, Europe, Asia-Pacific, and Rest of the World (RoW). The major factor driving the growth of this market is the growth of the global pharmaceutical industry. The adoption rate of membrane filtration in Europe and North America is very high. Further, increasing adoption rate in the Asia-Pacific segment and increasing demand for single use technology will further drive this market. Therefore, the pharmaceutical membrane filtration market is expected to witness a high growth in the forecast period. Membrane filtration is also used widely for protein purification in the pharmaceutical industry. Other important applications of this technology in the pharmaceutical industry are cell separation and water treatment. Microfiltration and ultrafiltration are the most widely used filtration technologies in the pharmaceutical industry. In 2013, Europe was the largest market for pharmaceutical membrane filtration. However, the North American market is expected to grow rapidly in the forecast period between 2013 and 2018 and is expected to be as large as that of Europe by 2018. Reasons to Buy the Report: - Market Penetration: Comprehensive information on product portfolios of top players in the pharmaceutical membrane filtration market. The report analyzes the pharmaceutical membrane filtration market by application across geographies. - Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical membrane filtration market. - Market Diversification: Exhaustive information about new technologies, applications, and emerging geographies in the pharmaceutical membrane filtration market. - Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the pharmaceutical membrane filtration market. Key Topics Covered: Introduction Executive Summary Market Dynamics Pharmaceutical Membrane Filtration Market - By Technology Pharmaceutical Membrane Filtration Market - By Application Pharmaceutical Membrane Filtration Market - By Geography Competitive Landscape Company Profiles List of Tables Companies Mentioned - 3M - Alfa Laval - GE - GEA Group - Graver Technologies - Koch Membrane Systems - MECO - Merck Millipore - Novasep - Pall Corporation - Sartorius Stedim Biotech - Spectrum Laboratories For more information visit http://www.researchandmarkets.com/research/kf...maceutical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PLL: 93.46 (-0.32), MRK: 59.07 (-0.47)
Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
M2 - Tue Aug 13, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq64s6/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets" report to their offering. 72 1024x768 Normal 0 false false false This new report, "Global Markets for Bioseparations for Biopharmaceutical Manufacturing," cites that the global market for bioseparations for biopharmaceutical manufacturing will grow to $6 billion by 2018. While North America and Europe will continue to account for a significant share of revenue, the emerging countries of China, India, Brazil and Russia are rapidly increasing share, growing at a CAGR of 22%. The demand for single use products is increasing and fueling growth of the global bioseparations market. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. The Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs, producing biosimilars for their own large populations and for Southeast Asia. bioseparations market. Membranes/filters will contribute $1.4 billion, followed by centrifuges ($400 million). The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report covers: Normal 0 false false false MicrosoftInternetExplorer4 The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report examines companies manufacturing biopharmaceutical manufacturing equipment and supplies in the world. Companies covered include: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/pq...separation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PLL: 93.46 (-0.32), A: 41.57 (+0.12), MRK: 59.07 (-0.47), DOW: 51.37 (+1.41), WAT: 112.48 (-1.24)
IV Fluid Transfer Devices Report - Products, Players, Markets and Opportunities
M2 - Wed Jun 26, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fnpmtc/iv_fluid_transfer) has announced the addition of the "IV Fluid Transfer Devices Products, Players, Markets and Opportunities" report to their offering. Intravenous drug administration is one of the most common therapeutic procedures that patients in a hospital setting are likely to receive. Yet the lack of standardization among the various components, elements and steps that a caregiver must navigate to successfully execute a drug intravenously have - according to several recent studies - contributed to medication errors and risks to patient safety. IV drug administration was once provided to patients only in clinical settings. However, technology developments and a greater emphasis on cost containment over the last 30 years have prompted a shift to providing this therapy in alternate settings, including the home. Highlights: - Analyzes the global market for IV fluid transfer devices market segments, and assesses the probable market
ICUI: 85.71 (+0.76), WST: 51.35 (-0.79), NVO: 44.13 (+0.11), CFN: 57.57 (+0.01)
ProMetic and Sartorius Stedim Biotech ("SSB"
Join Forces to Promote Novel Turnkey Solution for Producing Plasma-Derived Therapeutics Marketwire - Tue Apr 30, 4:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB" to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPS(TM) on a global basis. PLI.TO: 1.94 (-0.01)
Sartorius Stedim Biotech: Fact Sheet on New Reporting Format
Business Wire - Mon Apr 15, 1:32PM CDT
From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris
IM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech's business figures for 2012 as well as its earnings guidance for 2013 according to these changes. Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media
Business Wire - Wed Dec 19, 12:00AM CST
--Long-term collaboration, supply and distribution agreement with Swiss-based life science group Lonza
